olopatadine (nasal)

General

Pronunciation:
o-lo-pa-ta-deen


Trade Name(s)

  • Patanase

Ther. Class.

allergy, cold and cough remedies

Pharm. Class.

antihistamines

Indications

Seasonal allergic rhinitis.

Action

Antagonizes the effects of histamine at histamine1  receptor sites; does not bind to or inactivate histamine.

Therapeutic Effect(s):

Decreased symptoms of histamine excess including rhinorrhea, sneezing, and nasal itching.

Pharmacokinetics

Absorption: 57% absorbed from nasal mucosa.

Distribution: Unknown.

Metabolism and Excretion: Minimal metabolism; 70% eliminated in urine mostly as unchanged drug; 17% fecal elimination.

Half-life: 8–12 hr.

TIME/ACTION PROFILE

ROUTEONSETPEAKDURATION
Nasalrapidunknown12 hr

Contraindication/Precautions

Contraindicated in:

  • None noted.

Use Cautiously in:

  • Nasal pathology other than allergic rhinitis
  • OB:   Safety not established in pregnancy
  •  Lactation:  Safety not established in breastfeeding
  • Pedi:  Children <6 yr (safety not established).
  • Geri:  Dose cautiously in older adults; consider age-related ↓ in organ function and concurrent medications

Adverse Reactions/Side Effects

EENT: epistaxis, nasal perforation, nasal ulcerations, pharyngolaryngeal pain, postnasal drip

GI: bitter taste

Neuro: drowsiness, headache

Resp: cough

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

↑ CNS depression may occur with  alcohol ; avoid concurrent use.

Route/Dosage

Intranasal (Adults and Children  ≥ 12 yr): 2 sprays in each nostril twice daily.

Intranasal (Children 6–11 yr): 1 spray in each nostril twice daily.

Availability (generic available)

Nasal spray: 665 mcg/spray in 30.5-g bottle (provides 240 sprays)

Assessment

  • Assess for symptoms of seasonal allergic rhinitis (sneezing, runny nose, nasal itching) prior to and during therapy.

Implementation

  • Administer 2 sprays per nostril twice daily.

Patient/Family Teaching

  • Instruct patient to prime nasal spray by releasing 5 sprays or spraying until a fine mist appears before initial use. If unit has not been used within 7 days, re-prime with 2 sprays. Advise patient to discard nasal device after 240 sprays (30 days) even if bottle is not completely empty; correct amount of medication cannot be assured after 240 sprays.
  • May cause drowsiness. Advise patient to avoid driving or other activities that require alertness until response to medication is known.
  • Instruct patient to avoid concurrent use of alcohol or other CNS depressants.
  • Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Relief of symptoms of seasonal allergic rhinitis (rhinorrhea, sneezing, nasal itching).

olopatadine (nasal) is a sample topic from the Davis's Drug Guide.

To view other topics, please or .

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. .